The company's research collaboration and in-licensing have resulted in a robust structural chemistry platform. NexGenix's therapies are designed to provide targeted treatments for cancer, glioblastoma, neurodegenerative diseases, neurofibromatosis, and autism-spectrum disorders. The company's focus on protein homeostasis misregulation presents a unique opportunity for drug development for these varied disorders.